Van K. Morris
About
Van K. Morris is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research.
According to data from OpenAlex, Van K. Morris has authored 29 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 14 papers in Pathology and Forensic Medicine and 13 papers in Cancer Research. Recurrent topics in Van K. Morris's work include Colorectal Cancer Treatments and Studies (20 papers), Genetic factors in colorectal cancer (14 papers) and Cancer Genomics and Diagnostics (12 papers). Van K. Morris is often cited by papers focused on Colorectal Cancer Treatments and Studies (20 papers), Genetic factors in colorectal cancer (14 papers) and Cancer Genomics and Diagnostics (12 papers). Van K. Morris collaborates with scholars based in United States, Spain and United Kingdom. Van K. Morris's co-authors include Scott Kopetz, Kanwal Raghav, Michael J. Overman, David G. Menter, Michael Lam, Alexandra N. Willauer, Russell R. Broaddus, Andrea Hayes‐Jordan, Allan Andresson Lima Pereira and Funda Meric‐Bernstam and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
In The Last Decade
Van K. Morris
25 papers receiving 347 citations
Peers
Van K. Morris
Miguel Méndez Spain
Arteid Memaj United States
Trevor Feinstein United States
Shehara Mendis Australia
Sabina Murgioni Italy
Peter Kubiak United States
SC Linn Netherlands
Gary Zeger United States
Margherita Ambrosini Italy
Karin Berghoff Germany
Citations per year, relative to Van K. Morris Van K. Morris (= 1×)
peers
Miguel Méndez
Countries citing papers authored by Van K. Morris
Since
Specialization
Citations
This map shows the geographic impact of Van K. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Van K. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Van K. Morris more than expected).
Fields of papers citing papers by Van K. Morris
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Van K. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Van K. Morris. The network helps show where Van K. Morris may publish in the future.
Co-authorship network of co-authors of Van K. Morris
This figure shows the co-authorship network connecting the top 25 collaborators of Van K. Morris. A scholar is included among the top collaborators of Van K. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Van K. Morris. Van K. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yousef, Abdelrahman, Saikat Chowdhury, Michael J. Overman, et al.. (2025). BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy. npj Precision Oncology. 9(1). 38–38.
2.
Qiao, Wei, F. Anthony San Lucas, Keyur Patel, et al.. (2025). Prognostic value of circulating tumor DNA for progression-free survival in patients with locally advanced dMMR/MSI-H colorectal cancer managed without surgery.. Journal of Clinical Oncology. 43(4_suppl). 256–256.
3.
Willis, Jason, Arvind Dasari, Ryan Huey, et al.. (2025). Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF V600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies.. Journal of Clinical Oncology. 43(4_suppl). 182–182.
4.
Cook, Natalie, Mark Saunders, Scott Kopetz, et al.. (2024). 37P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patients. Annals of Oncology. 35. S19–S20.
5.
Lucas, F. Anthony San, Keyur P. Patel, Wai Chin Foo, et al.. (2024). Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer.. Journal of Clinical Oncology. 42(16_suppl). 3612–3612.
6.
Maurel, Joan, Van K. Morris, Scott Kopetz, et al.. (2024). 29P Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial. Annals of Oncology. 35. S14–S15.
7.
Morris, Van K., Katherine A. Guthrie, Scott Kopetz, et al.. (2024). SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS3640–TPS3640.
8.
Morris, Van K., Haifeng Zhu, Xiaoling Li, et al.. (2023). P-230 Biomarkers associated with survival benefit to atezolizumab and bevacizumab for treatment of metastatic anal cancer. Annals of Oncology. 34. S97–S97.
9.
Morris, Van K., Greg Yothers, Scott Kopetz, et al.. (2023). Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology. 41(4_suppl). TPS259–TPS259.
10.
Morris, Van K., Katherine A. Guthrie, Scott Kopetz, et al.. (2023). Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.. Journal of Clinical Oncology. 41(4_suppl). TPS265–TPS265.
11.
Johnson, Benny, Cara Haymaker, Van K. Morris, et al.. (2023). Abstract CT118: A phase I/II trial of a CXCR1/2 inhibitor in combination with anti-PD-1 for circulating tumor DNA (ctDNA) positive & refractoryRAS-mutated microsatellite stable (MSS) colorectal cancer. Cancer Research. 83(8_Supplement). CT118–CT118.
12.
Bhamidipati, Deepak, Kanwal Raghav, Van K. Morris, et al.. (2022). Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy.. Journal of Clinical Oncology. 40(16_suppl). 3524–3524.
13.
Kopetz, Scott, Van K. Morris, Bert H. O’Neil, et al.. (2022). A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.. Journal of Clinical Oncology. 40(16_suppl). TPS3637–TPS3637.
14.
Parseghian, Christine M., Stefania Napolitano, Jason Willis, et al.. (2022). Resistance mechanisms to anti-EGFR therapy in RAS/RAF wildtype colorectal cancer varies by regimen and line of therapy.. Journal of Clinical Oncology. 40(16_suppl). 3554–3554.
15.
Morris, Van K., Greg Yothers, Scott Kopetz, et al.. (2022). Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology. 40(4_suppl). TPS233–TPS233.
16.
Morris, Van K., Christine M. Parseghian, Benny Johnson, et al.. (2022). Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer.. Journal of Clinical Oncology. 40(16_suppl). 3598–3598.
17.
De, Brian, Kelsey L. Corrigan, Prajnan Das, et al.. (2021). Long-Term Patient-Reported Quality of Life and Functional Outcomes After Chemoradiation Using Intensity Modulated Radiotherapy for Anal Cancer. International Journal of Radiation Oncology*Biology*Physics. 111(3). S37–S38.
18.
Willauer, Alexandra N., Yusha Liu, Allan Andresson Lima Pereira, et al.. (2019). Clinical and molecular characterization of early‐onset colorectal cancer. Cancer. 125(12). 2002–2010.
19.
Morris, Van K. & Cathy Eng. (2018). Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. Journal of the National Comprehensive Cancer Network. 16(7). 903–908.
20.
Morris, Van K., Holly Spraker‐Perlman, Scott C. Howard, Russell E. Ware, & Ulrike M. Reiss. (2010). SEVERE THROMBOCYTOPENIA WITH IRON DEFICIENCY ANEMIA. Pediatric Hematology and Oncology. 27(5). 413–419.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Miguel Méndez Breakdown of academic impact, for papers by Arteid Memaj Breakdown of academic impact, for papers by Trevor Feinstein Breakdown of academic impact, for papers by Shehara Mendis Breakdown of academic impact, for papers by Sabina Murgioni Breakdown of academic impact, for papers by Peter Kubiak Breakdown of academic impact, for papers by SC Linn Breakdown of academic impact, for papers by Gary Zeger Breakdown of academic impact, for papers by Margherita Ambrosini Breakdown of academic impact, for papers by Karin Berghoff